Background/Aims: LINC00037 has previously been reported to be up-regulated in clear cell renal cell carcinoma (ccRCC), however, the underlying mechanism remained unknown. In this study, we designed to investigate the functional role of LINC00037 in ccRCC. Methods: LINC00037 knockdown and re-expressing 786-O and A498 cells were established. CCK8 assay and EdU assay were performed to evaluate the proliferation rates of ccRCC cells. Flow cytometry assay was performed to detect the cell apoptosis and cell cycle. Subcutaneous injection xenotransplantation mouse model was used to observe the role of LINC00037 in tumor growth in vivo of LINC00037 and RNA immunoprecipitation (RIP) was carried out to validate their interaction. Results: We found that knockdown of LINC00037 resulted in inhibited cell proliferation with activated apoptosis and cell cycle arrest in vitro. Over-expression of LINC00037 in LINC00037 knockdown cells restored and enhanced cell proliferation. In vivo mouse model indicated reduced tumor progression by LINC00037 depletion and promoted tumor progression by LINC00037 overexpression. LINC00037 could bind to epidermal growth factor receptor (EGFR) and increase the protein level of EGFR. Conclusion: LINC00037 could inhibit proliferation of ccRCC in an epidermal growth factor receptor-dependent way.
Introduction
Clear cell renal cell carcinoma (ccRCC) accounts for approximately 70% of renal cancer, which is one of the most common cancers, with approximately 202, 000 cases and 102, 000 deaths per year around the world [1, 2] . In clinical, RCC is characterized by anonymous symptoms and early metastasis [3, 4] . Early detection and selection of accurate targets for Long noncoding RNAs (lncRNAs) are non protein coding RNAs ranging from 200 nt early diagnosis and prognostic prediction for ccRCC [13, 14] .
occurrence and progression of ccRCC remain largely unknown.
Sequencing technologies and bioinformatics analyses are widely used to analyze LINC00037, which was high expressed its functional role in RCC cells and the underlying mechanism, which demonstrated that LINC00037 may be a therapeutic target for ccRCC.
Materials and Methods

Cell lines and animals
Shanghai, China).
were fostered in the absence of pathogen conditions. All the animals were subjected to humanitarian care, Animals. Subcutaneous xenotransplantation model LINC00037 in ccRCC and were inoculated into the mice were all killed and tumors were weighed. Tumor tissues were stripped as a whole.
Agarose gel electrophoresis Mass spectrometry (MS)
Polyacrylamide gel was made according to the standard protocol. Twenty microliters of each sample
Results
LINC00037 was highly expressed in ccRCC LINC00037
indicated by the homologous analysis (Fig. 1A) . Also, it is also reported as a non protein database (Fig. 1B) . LINC00037 LINC00037 in ccRCC consistently presented that LINC00037 was highly expressed in ccRCC compared with that of heathy mechanism in ccRCC.
LINC00037 promoted proliferation but not invasion of ccRCC cells in vitro
To detect the functional role of LINC00037 knockdown LINC00037 LINC00037
cells. When the expression of LINC00037 was rescued by LINC00037 LINC00037 LINC00037
role of LINC00037
LINC00037 inhibited apoptosis of ccRCC cells and alleviated cell cycle arrest
We further potential role of LINC00037 in regulating ccRCC cell apoptosis and cell LINC00037 was knockdown, ccRCC LINC00037 in ccRCC cells (Fig. 3A) . The cell cycle assay showed that LINC00037 knockdown LINC00037 in LINC00037
LINC00037 acted as a promoter of tumor growth in vivo
To study the effect of LINC00037 on tumor growth in vivo used to construct the xenotransplantation model through subcutaneously injection with LINC00037 transfected ccRCC cells. It showed that ccRCC cells after LINC00037 LINC00037 
Discussion
Studies on the expression patterns and regulatory mechanisms of functional lncRNAs biomarkers for ccRCC. In this study, we discussed the functional role of LINC00037 in ccRCC. We further explored its functional roles and the underlying mechanism in RCC cells, which demonstrated that LINC00037 is a potential therapeutic target for ccRCC. As described in the NCBI database, LINC00037, DGCR5 Nomenclature Committee. It is located at chromosome 22q11.21 with 2113 bp and has six LINC00037 was low expressed in LINC00037 was low expressed in LINC00037 predicted poor prognosis in pancreatic ductal LINC00037 LINC00037 LINC00037 expression patterns, the underlying mechanism of LINC00037 in cancer should
To study the function of LINC00037 LINC00037 in two LINC00037 in the former LINC00037 knockdown ccRCC cells. In vitro study showed that absence of LINC00037 
LINC00037
LINC00037 depletion, and the former LINC00037 in vivo that knockdown LINC00037 expressing LINC00037 is closely associated with its location. LncRNAs in cell nucleus often act as a transcription factor, whereas those in cytoplasm usually function through binding to certain proteins. To explore the subcellular location of LINC00037 separated nuclear and cytoplasm RNA was performed. The result showed that LINC00037 LINC00037 most differently enriched between two groups.
LINC00125
and LINC-EGFR LINC00037 knockdown in ccRCC cells, which 
